How much does stem cell therapy cost in 2024? How have prices changed? To authoritatively answer these questions now we need data from the present and past along with expert perspectives. Some surprises come up in this new analysis. In this article Intro | Stem Cell Therapy Cost: $10,000-$20,000 | Why do stem cells cost so much? […]
Stem cell therapy cost in 2024: data & analysis Read More »
It’s mostly been a week of good and encouraging news in the regenerative medicine space including with gene therapies maybe with the exception of some eye drops warnings (more below). There’s realistic hope for an approved sickle cell disease soon. I also see some long-term positive news on hearing loss research. Hematopoietic stem cell transplant
Weekly reads: reprogramming hearing loss, heart disease, eye drops, sickle cell Read More »
It’s a big challenge to get a cell therapy approved by the FDA and if you look at my list of FDA-approved stem cell therapies, it’s not as long as we might hope. FDA OK on cell therapy from Gamida Cell For this reason, it was excellent news to see that the FDA approved a
Weekly reads: FDA nod on new cell therapy, gray hair, pong-playing cells Read More »
The biotech Sarepta has had a complicated go of it with the FDA sometimes related to their Duchenne muscular dystrophy (DMD) gene therapy efforts. In late 2016 I wrote about how there was some controversy as the FDA approved the Sarepta drug eteplirsen (Exondys 51) also for DMD, going against an advisory panel that had
Weekly reads: Sarepta, epigenomics, FDA on eyedrops Read More »
What is the cell therapy for ALS called NurOwn? How strong is its potential as a treatment for ALS? I’ve been following the biotech BrainStorm Cell Therapeutics for many years. Patients keep asking me about NurOwn ALS prospects. They’re looking for hope. Today’s post is a close look at NurOwn and at BrainStorm as a
Does NurOwn from BrainStorm Cell Therapeutics still provide hope for ALS? Read More »
Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they
2023 stem cell & regenerative medicine predictions Read More »
If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »
The National Academy of Medicine elected a cohort of new members including three stem cell researchers. It’s great to see our field and these great scientists get recognition. The new NAM stem cell researchers include Sally Temple, Connie Eaves, and Tippie MacKenzie. Here’s a little bit about each of them. Dr. Temple is a stem cell biologist
Weekly reads: NAM dubs 3 stem cell researchers, kick the 2 buckets, stem cell homing Read More »
When I first started The Niche more than a dozen years ago, I hoped we’d see a Parkinson’s disease stem cell therapy by now. A proven one. I was a little too optimistic back then. Now in 2022, I know much better how hard translation to the bedside can be in general. Still, I’m hopeful.
Parkinson’s disease stem cell therapy research update Read More »
In today’s post I review the cord blood firm Cryo Cell International and discuss specific concerns I have about it. A major issue is their plan to open a clinic selling unproven cord cell infusions to kids. I believe this is risky both for the firm and more importantly for the children. What is Cryo
Cryo Cell reviews: dubious cord cell clinic plans, risks, other issues Read More »